Table 1.
Baseline characteristics and illness severity
| Variable | Placebo | Duloxetine |
|---|---|---|
| N = 140 | N = 151 | |
| Age, mean (SD) years | 71.7 (5.0) | 71.4 (5.4) |
| Female, n (%) | 112 (80.0) | 114 (75.5) |
| Ethnicitya | ||
| African descent, n (%) | 0 | 5 (3.3) |
| Caucasian, n (%) | 120 (85.7) | 129 (85.4) |
| Native American, n (%) | 18 (12.9) | 17 (11.3) |
| MMSE total score, mean (SD) | 28.5 (1.7) | 28.4 (1.7) |
| CGI-S, mean (SD) | 4.4 (0.6) | 4.4 (0.6) |
| HAM-A total score, mean (SD) | 24.4 (7.1) | 24.6 (6.4) |
| HAM-A Psychic Anxiety Factor score, mean (SD) | 13.4 (3.4) | 13.6 (3.2) |
| HAM-A Somatic Anxiety Factor score, mean (SD) | 10.9 (4.8) | 11.0 (4.3) |
| HADS Anxiety subscale score, mean (SD) | 13.6 (3.3) | 13.9 (3.1) |
| HADS Depression subscale, mean (SD) | 7.4 (4.3) | 7.4 (3.9) |
| SDS Global Functional Impairment score, mean (SD) | 14.2 (7.5) | 13.7 (7.6) |
| Q-LES-Q-SF, mean % of maximum score (SD) | 49.3 (14.6) | 49.0 (14.0) |
| BPI 24-h Average Pain Severity, mean (SD) | 3.2 (2.6) | 3.1 (2.6) |
| BPI Pain Interference, mean (SD) | 3.0 (2.4) | 2.8 (2.3) |
SD, standard deviation; BPI, Brief Pain Inventory; CGI-S, Clinical Global Impressions–Severity of Illness; HADS, Hospital Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; MMSE, Mini mental state examination; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form; SDS, Sheehan Disability Scale.
There were no significance between treatment group differences in any of the baseline variables.
a
Two patients in the placebo group (1.4%) did not report ethnicity/race information.